DB959 is a peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist which activates certain nuclear receptors that regulate the genes involved in controlling blood sugar levels and certain lipids.
The double-blind, escalating multiple dose, placebo-controlled, randomized trial that enrolled 32 healthy male and female volunteers was designed to study the safety and efficacy of DB959.
The results showed that DB959 is safe and well-tolerated and show support for pharmacological activity.
DARA CEO Richard Franco said DB959 is entering Phase 2 with a positive track record from both preclinical and now Phase 1 clinical studies.